/
 Management of Atrial Fibrillation, Stroke, and Bleeding  Management of Atrial Fibrillation, Stroke, and Bleeding

Management of Atrial Fibrillation, Stroke, and Bleeding - PowerPoint Presentation

natalia-silvester
natalia-silvester . @natalia-silvester
Follow
344 views
Uploaded On 2020-04-10

Management of Atrial Fibrillation, Stroke, and Bleeding - PPT Presentation

MetaAnalysis of NOACs vs Warfarin RCT vs RealWorld Data Screening for Atrial Fibrillation to Prevent Strokes Silent AF Screening for AF Devices for LongTerm AF Screening Regular Pulse Check for Detecting AF ID: 776667

noac noacs ich screening noac noacs ich screening detecting registry reversal meta analysis abbreviations warfarin related devices real world

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document " Management of Atrial Fibrillation, Stro..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Management of Atrial Fibrillation, Stroke, and Bleeding

Slide2

Meta-Analysis of NOACs vs Warfarin

Slide3

RCT vs Real-World Data

Slide4

Screening for Atrial Fibrillation to Prevent Strokes

Slide5

Silent AF

Slide6

Screening for AF

Slide7

Devices for Long-Term AF Screening

Slide8

Regular Pulse Check for Detecting AF

Slide9

Implantable vs Handheld Devices for Detecting AF

Slide10

Implications of Screening and Detecting AF

Slide11

NOAC-Related Intracranial Hemorrhage

Slide12

Incidence of ICH in NOAC-Treated Patients

Slide13

Predictors of ICH

Slide14

Handling Patients With ICH

Slide15

Slide16

Resuming Anticoagulation After a Bleed

Slide17

Oral Anticoagulants

Slide18

Clinical Trials vs "Real-World" Studies

Slide19

Sources of Data in AF With NOAC

Slide20

Registry DataUse of Low Doses of NOACs

Slide21

Misconceptions About NOAC Doses

Slide22

Registry DataExtremes of Age and Weight

Slide23

Registry DataAdherence

Slide24

Take-Home Messages

Slide25

NOACs

Slide26

Meta-Analysis of NOACs vs Warfarin

Slide27

Use of PCC in NOAC-Related ICH

Slide28

Specific Reversal Agents

Slide29

Indications for Reversal Agents

Slide30

NOAC Assays

Slide31

Dosing Strategies for Idarucizumab vs Andexanet Alfa

Slide32

Abbreviations

Slide33

Abbreviations (cont)